Rib-X Skips IPO, Opts for $67.5M Equity Financing
By Catherine Shaffer
Friday, November 30, 2012
Rib-X Pharmaceuticals Inc. walked back from its proposed initial public offering (IPO) filed almost exactly a year ago, arranging instead for a $67.5 million Series 2 preferred stock financing led by a new investor, Vatera Healthcare Partners.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.